share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 20 16:32
Summary by Moomoo AI
On February 20, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, announced its ongoing collaboration with Clearmind Medicine Inc., a biotech company developing psychedelic-derived therapeutics. Together, they are strengthening their international patent portfolio with the filing of three new patent applications under the Patent Cooperation Treaty. These applications focus on novel combinations of psychedelic compounds, including LSD, psilocybin, DMT, and SciSparc's proprietary ingredient CannAmide™. The patents, initially filed as provisional applications with the USPTO, aim to leverage the therapeutic advantages of these compounds. SciSparc's CEO, Oz Adler, expressed confidence in the value CannAmide™ adds to psychedelic therapeutics. The company is also advancing drug development programs for various conditions, including Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus, and owns a subsidiary selling hemp seed oil-based products on Amazon.
On February 20, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, announced its ongoing collaboration with Clearmind Medicine Inc., a biotech company developing psychedelic-derived therapeutics. Together, they are strengthening their international patent portfolio with the filing of three new patent applications under the Patent Cooperation Treaty. These applications focus on novel combinations of psychedelic compounds, including LSD, psilocybin, DMT, and SciSparc's proprietary ingredient CannAmide™. The patents, initially filed as provisional applications with the USPTO, aim to leverage the therapeutic advantages of these compounds. SciSparc's CEO, Oz Adler, expressed confidence in the value CannAmide™ adds to psychedelic therapeutics. The company is also advancing drug development programs for various conditions, including Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus, and owns a subsidiary selling hemp seed oil-based products on Amazon.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more